相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma
Lauren J. Mills et al.
BONE (2022)
Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
Jacob R. Cawley et al.
FRONTIERS IN VETERINARY SCIENCE (2022)
Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, Naked Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells
Elena G. Varlamova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines
Sarinya Palakhachane et al.
BIOORGANIC CHEMISTRY (2021)
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib)
Jung-Hyun Kim et al.
VETERINARY QUARTERLY (2021)
In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models
Raquel Sanchez-Cespedes et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2020)
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
Laura Marconato et al.
CANCERS (2020)
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
Imane El Dika et al.
CANCER MEDICINE (2020)
Genome-Informed Targeted Therapy for Osteosarcoma
Leanne C. Sayles et al.
CANCER DISCOVERY (2019)
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
Ghassan K. Abou-Alfa et al.
JAMA ONCOLOGY (2019)
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2
Heather L. Gardner et al.
COMMUNICATIONS BIOLOGY (2019)
Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma
T. Laver et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2018)
SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
Sharadha Sakthikumar et al.
CANCER RESEARCH (2018)
Sorafenib in patients with progressed and refractory bone tumors
Anna Raciborska et al.
MEDICAL ONCOLOGY (2018)
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Giorgia Marisi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Hepatocellular Carcinoma: Review of Targeted and Immune Therapies
Daniel da Motta Girardi et al.
JOURNAL OF GASTROINTESTINAL CANCER (2018)
Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Mary E. Spilker et al.
CLINICAL CANCER RESEARCH (2017)
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Kuisheng Liu et al.
CELL DEATH & DISEASE (2017)
Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
Amanda Foskett et al.
VETERINARY MEDICINE-RESEARCH AND REPORTS (2017)
Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Dane R. Liston et al.
CLINICAL CANCER RESEARCH (2017)
In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs
Jia-Xue Yin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method-Letter
John C. Ashton
CANCER RESEARCH (2015)
Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study
D. Jaeger et al.
CLINICAL GENITOURINARY CANCER (2015)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis
Branden S. Moriarity et al.
NATURE GENETICS (2015)
RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?
Richard Cathonnas et al.
ONCOLOGY (2015)
Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs
Kevin Marley et al.
TRANSLATIONAL ONCOLOGY (2015)
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
Cheryl A. London et al.
PLOS ONE (2015)
What do we know about canine osteosarcoma treatment? - review
M. Szewczyk et al.
VETERINARY RESEARCH COMMUNICATIONS (2015)
VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment
Jiong Mei et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2014)
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
Niels Eckstein et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Comparison of Carboplatin and Doxorubicin-Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma
L. E. Selmic et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2014)
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS
Ingrid Walter et al.
ONCOLOGY REPORTS (2014)
Evaluation of ifosfamide salvage therapy formetastatic canine osteosarcoma
K. Batschinski et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2014)
SC-1, A Sorafenib Derivative, Shows Anti-Tumor Effects in Osteogenic Sarcoma Cells
Chen-Ti Wang et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2013)
A case study of personalized therapy for osteosarcoma
Lara E. Davis et al.
PEDIATRIC BLOOD & CANCER (2013)
Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B
Elinor K. Karlsson et al.
GENOME BIOLOGY (2013)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma
Bing Tu et al.
CANCER LETTERS (2012)
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours
C. London et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2012)
Targeting Inflammatory Kinase as an Adjuvant Treatment for Osteosarcomas
Kyucheol Noh et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2011)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Pharmacokinetic Modeling of Doxorubicin Pharmacokinetics in Dogs Deficient in ABCB1 Drug Transporters
D. L. Gustafson et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2010)
Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program
Stephen T. Keir et al.
PEDIATRIC BLOOD & CANCER (2010)
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line
B. Wolfesberger et al.
RESEARCH IN VETERINARY SCIENCE (2010)
Characterization of STAT3 activation and expression in canine and human osteosarcoma
Stacey L. Fossey et al.
BMC CANCER (2009)
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Cheryl A. London et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
B. Blanchet et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Ymera Pignochino et al.
MOLECULAR CANCER (2009)
Pharmacokinetic Comparison Between Systemic and Local Chemotherapy by Carboplatin in Dogs
Chunlin Chen et al.
REPRODUCTIVE SCIENCES (2009)
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
Hironobu Minami et al.
CANCER SCIENCE (2008)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A. Gollob et al.
SEMINARS IN ONCOLOGY (2006)
Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004)
SE Boston et al.
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (2006)
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
D Strumberg
DRUGS OF TODAY (2005)
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada et al.
BRITISH JOURNAL OF CANCER (2005)
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog
D McKillop et al.
XENOBIOTICA (2004)
分享论文
